Doctor explaining Doctor explaining

For Your Patients

The ProAir® HFA support library

We want to help you give patients the best care possible. ProAir HFA support is always here to help you teach patients about asthma, exercise-induced bronchospasm (EIB), chronic obstructive pulmonary disease (COPD), and how ProAir HFA can help. Look into the resources below

Asthma resources

EIB resources

COPD resources

Patient assistance

Teva Cares Foundation Patient Assistance Program

Teva Respiratory is committed to providing patients with
high-quality medicines for asthma, COPD, and EIB. Your patient may qualify for
assistance from the Teva Cares Foundation if you meet the conditions below.

To qualify for assistance from this program, patients must:

1.Be a resident of the United States, Puerto Rico, or the US Virgin Islands.

2.Not be eligible for any prescription drug benefits through any private or public insurer/payer/program.

3.Have a total family annual income of 300% or below the federal poverty level for their state.

4.Have a prescription for one or more of the Teva medicines listed on the application.

To enroll your patient, download a copy of the Teva Cares Foundation application
  • Patients will be notified by mail of program acceptance or denial
  • If the patient is approved, you will receive a form to complete and return
  • Medicine(s) will be shipped to your office directly from the Teva pharmacy
  • Once approved, patients are eligible to receive assistance for up to 12 months
  • Renewals will be handled on a per-patient basis

Questions? Please call the Teva Cares Foundation toll free at 1-877-237-4881.


ProAir HFA (albuterol sulfate) Inhalation Aerosol is indicated in patients ≥4 years of age for the treatment or prevention of bronchospasm with reversible obstructive airway disease and in patients ≥4 years of age for the prevention of exercise-induced bronchospasm.

Important Safety Information

  • Contraindications: ProAir HFA is contraindicated in patients with hypersensitivity to albuterol
  • Paradoxical Bronchospasm: ProAir HFA can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir HFA and institute alternative therapy if paradoxical bronchospasm occurs
  • Deterioration of Asthma: Need for more doses of ProAir HFA than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids
  • Use of Anti-Inflammatory Agents: ProAir HFA alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids
  • Cardiovascular Effects: ProAir HFA, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir HFA, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
  • Do Not Exceed Recommended Dose: Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma
  • Immediate Hypersensitivity Reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema
  • Coexisting Conditions: ProAir HFA, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.
  • Hypokalemia: As with other beta-agonists, ProAir HFA may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation
  • Most common adverse reactions (≥3.0% and >placebo): are headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis
  • Drug Interactions: Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir HFA
    • Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir HFA, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers
    • Diuretics: Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels
    • Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir HFA
    • Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir HFA should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy

  • Please read the full Prescribing Information.